

FORM 51-102F3

Material Change Report

Item 1. Name and Address of Company

Blackhawk Growth Corp. (the “Company”)
Suite 2200, 885 West Georgia Street
Vancouver, B.C., V6C 3E8

Item 2. Date of Material Change

News Release dated February 8, 2021

Item 3. News Release

The Company disseminated a news release concerning the material change described herein on February 8, 2021 and subsequently filed a copy on SEDAR at www.sedar.com.

Item 4. Summary of Material Change

Blackhawk Growth submits requested additional information pertaining to the ExProbe SARS-CoV-2 Health Canada interim order submission & receives correspondence regarding SARS-CoV-2 IgG/IgM Rapid Test Kit review.

Item 5. Full Description of Material Change

Vancouver, British Columbia – February 8, 2021 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:OJJ); (CNSX:BLR.CN); (OTC:BLRZF) (the “Company”), has submitted the required additional information for its ExProbe SARS-CoV-2 Testing Kit Health Canada Interim Order (“IO”) Submission. The Corporation received correspondence from Health Canada on Friday, January 8th requesting additional information to be provided for its ExProbe SARS-CoV-2 Testing Kit. Health Canada provided a timeline of 10 days to submit the information with the option of (up to) a 30-day extension that the corporation acted on. Blackhawk is pleased to say all 227 pages of requested documentation have been compiled and submitted to Health Canada on the agreed upon date of February 6th 2021.

Blackhawk is also pleased to announce that it has received correspondence from Health Canada on Friday, January 29th regarding its SARS-CoV-2 IgG/IgM Rapid Test Kit application which is now “under review”. The corporation has taken the position that Health Canada is now actively reviewing the IO. The Health Canada Interim Order (“IO”) for its SARS-CoV-2 IgG / IgM Rapid Test Kit application was submitted on November 4th, 2020 requesting additional information to be provided for its ExProbe SARS-CoV-2 Testing Kit. Blackhawk is working with the manufacturer and its compliance team to ensure the requested information is provided in short-order. Health Canada has provided a timeline of 10 days to submit the information with the option of a 30-day extension if required.

Blackhawk will continue to update its shareholders as the application process with Health Canada proceeds.

Blackhawk makes no representations or provides any guarantees on Health Canada's review timelines.

About Blackhawk Growth

Blackhawk Growth is an investment issuer looking to create substantial value for our shareholders through the acquisition and development of high growth opportunities. The company has focused its investments in the health, cannabis and CBD industries in both Canada and the United States. Its portfolio of companies include Sac Pharma, Trip Pharma, Noble Hemp, Spaced Food and NuWave Foods.

For further information please contact:

Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com

.Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable

Item 7. Omitted Information

Not applicable

Item 8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels
Chief Executive Officer
Telephone: 403-991-7737

Item 9. Date of Report

February 8, 2021